SAN DIEGO, Nov. 14, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported financial results for the three months and the nine months ended September 30, 2013.
"We have made significant corporate and scientific achievements in recent months. We have signed multiple collaboration agreements and launched our first oncogene mutation detection test. In addition, the first series of clinical results were presented at a major medical conference.
Help employers find you! Check out all the jobs and post your resume.
